New Immune-Boosting drugs tested in advanced cancer patients

NCT ID NCT04752215

Summary

This early-stage study tested two new immunotherapy drugs, BI 765049 and ezabenlimab, in adults with advanced solid tumors that had stopped responding to standard treatments. The main goal was to find the highest safe dose of these drugs, either alone or in combination, that patients could tolerate. Doctors monitored patients for up to 3 years to check for side effects and see if the treatment helped shrink their tumors.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLORECTAL NEOPLASMS, CARCINOMA, NON-SMALL-CELL LUNG, PANCREATIC NEOPLASMS, CARCINOMA, HEPATOCELLULAR, HEAD AND NECK NEOPLASMS, GASTROINTESTINAL NEOPLASMS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Baylor University Medical Center

    Dallas, Texas, 75246, United States

  • Florida Cancer Specialists-Sarasota-61670

    Sarasota, Florida, 34232, United States

  • HealthONE

    Denver, Colorado, 80218, United States

  • MD Anderson Cancer Center Orlando

    Orlando, Florida, 32806, United States

  • Mary Crowley Cancer Research Center

    Dallas, Texas, 75230, United States

  • New York University Langone Medical Center

    New York, New York, 10016, United States

  • Northwestern University

    Chicago, Illinois, 60611, United States

  • Norton Healthcare - Norton Cancer Institute - Louisville

    Louisville, Kentucky, 40202, United States

  • Princess Margaret Cancer Centre

    Toronto, M5G 1Z5, Canada

  • Stephenson Cancer Center

    Oklahoma City, Oklahoma, 73104, United States

  • Tennessee Oncology, PLLC-Nashville-52568

    Nashville, Tennessee, 37203, United States

  • University of Alabama at Birmingham

    Birmingham, Alabama, 35294, United States

  • University of California Irvine

    Orange, California, 92868, United States

  • Valkyrie Clinical Trials

    Los Angeles, California, 90067, United States

Conditions

Explore the condition pages connected to this study.